NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
SparingVision Presents Initial SPVN06 Safety Data at the Macula Society 47th Annual Meeting<
08 Feb 2024

SparingVision Presents Initial SPVN06 Safety Data at the Macula Society 47th Annual Meeting

Enrollment and treatment of the third cohort, comprising three patients at a higher dose, are underway.
Mineralys Therapeutics Announces $120 Million Private Placement Financing<
08 Feb 2024

Mineralys Therapeutics Announces $120 Million Private Placement Financing

The financing was led by new investor TCGX and existing investor RA Capital Management
Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland<
08 Feb 2024

Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland

MAF Test® could increase the survival of 80% of the 56,000 early-stage breast cancer patients diagnosed each year.
Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy<
01 Feb 2024

Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy

Funding from French Government as part of the France Health Innovation Plan 2030 operated by Bpifrance
Lava Therapeutics announces collaboration with Merck & co., inc., Rahway, NJ, USA to evaluate Lava-1207 in combination with Keytruda®<
26 Jan 2024

Lava Therapeutics announces collaboration with Merck & co., inc., Rahway, NJ, USA to evaluate Lava-1207 in combination with Keytruda®

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa<
24 Jan 2024

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa

Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling progression to highest dose of Part 1 of the PRODYGY trial
Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510<
18 Jan 2024

Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510

1. Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System

Am-Pharma initiates Phase 2 trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage<
16 Jan 2024

Am-Pharma initiates Phase 2 trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage

Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer<
04 Jan 2024

Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

Dr. Kim brings more than two decades of experience in business development, strategic leadership, and scientific research
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia<
04 Jan 2024

Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia

Topline results are expected in the second half of 2024

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка